Related Experiment Video
Updated: Dec 15, 2025

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
Altered age-linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHT-preAD study) with high brain
Jean M Delabar1,2, Marion Ortner3, Stephanie Simon4
1INSERM U 1127, CNRS UMR 7225 UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et la Moelle épinière, ICM Sorbonne Universités Paris France.
Introduction:
An effective therapy has not yet been developed for Alzheimer's disease (AD), in part because pathological changes occur years before clinical symptoms manifest. We recently showed that decreased plasma DYRK1A identifies individuals with mild cognitive impairment (MCI) or AD, and that aged mice have higher DYRK1A levels.
Methods:
We assessed DYRK1A in plasma in young/aged controls and in elderly cognitive complainers with low (L) and high (H) brain amyloid load.
Results:
DYRK1A level increases with age in humans. However, plasma from elderly individuals reporting cognitive complaints showed that the H group had the same DYRK1A level as young adults, suggesting that the age-associated DYRK1A increase is blocked in this group. L and H groups had similar levels of clusterin.
Discussion:
These results are reflective of early changes in the brain. These observations suggest that plasma DYRK1A and not clusterin could be used to classify elderly memory complainers for risk for amyloid beta pathology.
Insights
Plasma DYRK1A levels may help identify early Alzheimer's disease (AD) risk. Higher DYRK1A in cognitively impaired individuals suggests a blockage of age-related increases, potentially indicating early brain changes and amyloid beta pathology.
Area of Science:
- Neuroscience
- Biochemistry
- Aging Research
Background:
- Effective Alzheimer's disease (AD) therapies are lacking, partly due to pre-symptomatic pathological changes.
- Decreased plasma DYRK1A levels have been linked to mild cognitive impairment (MCI) and AD.
- Aged mice exhibit elevated DYRK1A levels, suggesting an age-related DYRK1A increase.
Purpose of the Study:
- To investigate DYRK1A levels in plasma of elderly individuals with varying cognitive status and brain amyloid load.
- To determine if plasma DYRK1A can serve as a biomarker for early detection of amyloid beta pathology in memory complainers.
Main Methods:
- Assessed DYRK1A levels in plasma from young/aged controls and elderly individuals reporting cognitive complaints.
- Categorized elderly participants into low (L) and high (H) brain amyloid load groups.
- Measured clusterin levels for comparison.
Main Results:
- Human DYRK1A plasma levels increase with age.
- Elderly individuals with high amyloid load (H group) showed DYRK1A levels similar to young adults, indicating a blocked age-associated increase.
- Clusterin levels were comparable between L and H groups.
Conclusions:
- Plasma DYRK1A levels reflect early brain changes associated with cognitive decline.
- Plasma DYRK1A, unlike clusterin, shows potential as a biomarker for classifying elderly memory complainers at risk for amyloid beta pathology.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Neural Regulation
Pharmacodynamics in Geriatric Patients: Effects of Age
Drug Dosing: Geriatric Patients
Dementia
The progression of dementia is generally gradual....
Cognitive Development During Adulthood

